Pegcetacoplan · intravitreal injection
Injections & Implants
Approved uses
Geographic atrophy secondary to age-related macular degeneration
15 mg (0.1 mL of 150 mg/mL) intravitreally into each affected eye every 25 to 60 days
Slows lesion growth without restoring acuity, and raises the risk of converting to neovascular AMD
Contraindications
- Ocular or periocular infection
- Active intraocular inflammation
- Hypersensitivity to pegcetacoplan or any excipient in SYFOVRE
15 mg (0.1 mL of 150 mg/mL solution), single-dose glass vial; Vial Only or Vial Kit with Injection Components
Pegcetacoplan binds to complement protein C3 and its activation fragment C3b with high affinity thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation.
Warnings & Precautions
- Endophthalmitis and Retinal Detachments: Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
- Retinal Vasculitis and/or Retinal Vascular Occlusion: Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay.
- Neovascular AMD: In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.
- Intraocular Inflammation: In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves patients may resume treatment with SYFOVRE.
- Increased Intraocular Pressure: Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.
Common Side Effects
The most common adverse reactions (≥5%) reported in patients receiving SYFOVRE were ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, and conjunctival hemorrhage.
Pregnancy: No adequate and well-controlled studies in pregnant women to inform a drug-associated risk; use may be considered after weighing risks and benefits.
Lactation: It is not known whether intravitreal administered pegcetacoplan is secreted in human milk or whether there is potential for absorption and harm to the infant. Caution should be exercised when SYFOVRE is administered to a nursing woman.
The safety and effectiveness of SYFOVRE in pediatric patients have not been established.